Okay. Thanks. Welcome all again to the Stifel Conference. I'm Christian Glennie, healthcare analyst at Stifel based in London. Delighted to be joined by, here on stage, by Nick Keher, CFO of Oxford Nanopore. Just by way of brief background, Nanopore is London-listed, GBP 2.7 billion market cap, life sciences tools business focused on the global commercialization of its nanopore-based long-read sequencing technology for genetic and genomic analysis. Maybe let's just start there a little bit, brief overview of Nanopore today in terms of your technology proposition, your differentiation versus some other key technologies on the market, and then we'll take it on.
Yeah. Thank you, and thank you very much for the invitation as well. Apologies for getting a bit late, getting through the lifts. Oxford Nanopore, we are 1,350 people, as you say, FTSE 250 listed, 22 years old, spun out of Oxford University on the basis of having a single molecular sensing platform. We're experts at making very small holes, nanopores, they're about the thousandth the width of a human hair, and through that we pass DNA, RNA, and now protein. Essentially, as the DNA, RNA, protein goes through the nanopore, it changes the electrical current that we pass through, much like an ECG, and then we translate that with machine learning AI into letters, ATGC, in the case of DNA, and then into a picture of what the genome looks like. This is a novel platform.
The way we approach it is we develop the best nanopore possible to act as a microscope, essentially as that single molecular sensing platform, and it's very different to the established technologies today because we don't take a copy of the DNA, we don't cut it up into smaller pieces, we don't amplify it, and that means we keep the richness, the color of the DNA, RNA, protein as well. So, our proposition is that because we look at this in the DNA in all its form, we get all of the methylation, all of the color. We get any read length, which means that we get the long-read structural variations as well as the short-read information as well. And because we're looking at this from an electrical-based sensing platform, we get the real-time information as well.
Lastly, because this is nanopores and a thousandth the width of a human hair, we can miniaturize this tech. So, it's a unique proposition versus the other established platforms that are out there. We're 12 years commercial now, been growing consistently over 20% a year, GBP 250 million in revenues last year, and yeah, we think there's a lot of opportunity for us to kind of go further, where we're focusing now on our target application areas where we offer a right to win because of the differentiation of the platform against those established other technologies, and we're seeing that uptake accelerate as well.
Okay, thank you. In terms of, we'll dig into the specific end users and market opportunities of those segments, but I guess just initially, high level, your key areas of target focus in terms of the end user applications and target markets, and how you're going after some of those markets.
Yeah, absolutely. Today, 65% of our revenues are within the research and government space, and we have about 15% of our revenues within clinical, 8% within biopharma, and then the balance within industrial markets as well. We have a 450-person strong commercial workforce that essentially is driving that adoption with our customer base, and we have a number of collaborators, partners as well, to help accelerate uptake in those markets. Now, it's different by end market where we're focusing. We have specialists in our teams, we have generalists, and essentially it depends on the account managers who they're targeting from an end market perspective.
You can imagine, the platform has been developed for the research customer base in the first instance, but what we're seeing is real uptake now in that like third of our business, which we call applied, which is your biopharma, clinical, and industrial markets, and that's where we're seeing quite a few of our target application areas that we want to go for, and so where we're doubling down. We spent the last year, two years nearly now, refining our where to play. Essentially looking at where we can offer real differentiated value to the customer, and then where we have a right to win from a commercialization perspective, so we can have pricing ultimately as well, because the market is quite challenged otherwise. Now we're looking at how to play, and that comes down to our partnering strategy, where we go direct instead.
What this has kind of showed is, within clinical, we have a very large market opportunity for us, GBP 10 billion essentially in total. We believe the best way of approaching this is to focus on a specific number of use case target applications within infectious disease, rare disease, and oncology, and then it's to partner effectively, because we don't have a tertiary analysis capability that customers will need for a lockdown report, so we've got to partner with people that do. From a sample prep automation perspective, we absolutely need to partner there with companies that can allow us to scale effectively for the customer base. But we will own the center, which is the sequencing, basecalling, sample prep elements.
When we look at biopharma, because of the smaller number of customers that are there, particularly when we look at the quality control target application areas we are focused on, like mRNA, we are going to be going direct because we can actually offer a solution to the customer instead. We have spent a lot of time segmenting these target application areas, about 15 of 47 that we are really going to narrow down on, where we think we have got right to win, and we have got a very clear how we are going to play in these markets now as well. It is either direct, 450 people on the ground, or servicing the customers, or in conjunction with partners as well.
Sorry, 15 of 47 was what, sorry.
End markets.
End.
What we have done as part of this exercise is there is about 47 end markets where sequencing is today, or where it will be tomorrow. Infectious disease is a very big end market, for instance, rare disease, or biopharma quality control. Then we have essentially scattered those over an X-Y axis of right to win, like a tech differentiation on the X axis, on the Y axis, ease of commercialization, and that is how we have kind of come up with our playbook for how we are going to go about it. Because being completely frank, short-read sequencing is very effective in certain indications, and the price point is right. You are never going to convert those unless you really want to double down on making something incredibly cheap. That is not what we want to do.
We want to focus in areas where we offer real value from a richness of insight, speed, form factor, that means that we can win.
Okay. Yep, that's helpful. Maybe just to, obviously, just touch on the research part, still the 65% of the business today, 5% growth in the first half. Just generally, how are you seeing that market today, budgets, and generally as an outlook for that part of that sort of still core market today, but how does that evolve?
Yeah. So, without a doubt, it's very challenging out there, particularly in the U.S., given the whole NIH issues that everybody's well-documented on. But we were only 5% growth in the first half because of the fact we had about $10 million worth of contracts rolling off from the prior year. NIHR, actually in EMEA, GEL 2.0 in EMEA as well, and then APAC, we had the PRECISE 2 contract. So those, that's about collectively about $10 million of work that didn't repeat in the first half of this year. If you added that back on, we're high teens, actually. And that's a good proxy for the underlying number. As we go into the second half, we expect that number to improve.
As we look forward, we think we can sustain, as we've said before, at results, we can sustain a low teens growth rate out to 2030 for the research segment as a whole. Now, that's in spite of the end markets being particularly weak. And the reason why that is because we believe, and I think our customers see, we add more value over conventional technologies, and that's why we're still being adopted. So even though the tide may be out, we're still being able to grow. We just hope that there was a rising tide that lifted all boats in a bit of a quicker manner. And that we're not seeing any real change in the NIH part. So, it's still tough out there. Things are happening.
Irrespective of whether that-
Yeah
underlying market changes in your favor.
We will still grow at that low teens rate till 2030 as a minimum. That is because the adoption curve is still early stages. We just hope that the market improves, and who knows, given the changes recently, maybe NIH funding comes back.
Yep. Thank you. Let us then turn to these other key market, applied market opportunities. Biopharma, you have called out there, relatively small part of the business today, but maybe you could just illustrate by way of example. I mean, you have disclosed publicly, you have got an agreement with Lonza on mRNA quality control. So, what is it that you are applying technology to solve? What problem is it you are trying to solve with your technology, and when does that start to scale in those opportunities? Thanks.
Yeah. mRNA is a perfect one, and given the recent trial results of certain companies, it is a very prominent one as well. We have developed a workflow for mRNA QC, and this is the problem that we are solving here for the customer, is we are consolidating multiple different tests into one on our own platform that is going to allow companies to scale commercially. It is also going to lower the cost and the time, the vein-to-vein time, which is incredibly important in this space. The reason why we can do this is because we look at the RNA directly, which means that we can see the modifications that are on the vaccine itself. The critical quality attributes that we are looking at are identity, integrity, and purity. There are like five specific things we are looking at within those three.
Now, at the beginning, or the first product that we have got launched already is looking at identity, and it is replacing Sanger and one other technology that is essentially used today. We are adding on integrity and purity, and that is going to broaden out the total CQAs to about five, and it will replace several orthogonal tests that are done today. This is incredibly important because when these companies scale, every patient is now a batch, and every batch needs to be quality control checked before it is released. If you want to scale to 100,000 patients or even 20,000 patients, if you want to do that on these conventional platforms, you may be talking a month, you may be talking huge labor-intensive processes, versus on us, where we can do it in a few days and on one product line.
We have walked around facilities of, and we are working with Lonza, and we have a GMP-qualified test with them, but we are also going direct to the big manufacturers in the space, who have talked at our customer events, so people want to go check all that out on LinkedIn. These companies are essentially using us for precisely these reasons. When we have walked around their manufacturing facilities as a preferred supplier, what we have seen essentially is that, if they are going to scale, they are going to need our platform to do it. We are answering a big problem there, and that vein-to-vein is also really important in this space. For us, just to scale the size of the opportunity, list price is like $2,000 a test per batch, so per patient. Maybe in a melanoma, they are talking like 20,000, 25,000 patients.
Once we add on these other CQAs, we would hope to be able to maybe improve on pricing again. That is all before discounting, and we have said to investors and analysts, "Work on maybe $1,000 full discounting for the first CQA for people, for the customers. But once we add on these other CQAs, maybe it is higher again." People have always asked, "What is the killer application for Nanopore?" We have lots, but this is the one where we can see it is coming of age now. Given the excitement around the personalized cancer vaccine space, we think it is other people are getting excited as well.
Yeah. There was talk, we'll talk about interims or sort of reference to obviously Moderna and their data, but more broadly, you talked about sort of 20 potential customers here, biopharma customers evaluating the technology, putting into workflows. Just to pick up a bit of a nuance there, is it the contract manufacturers that are more your end customers, or is it also the actual biopharma company developing that cancer vaccine or whatever?
Both. We are working directly with the mRNA players as well, as well as through a CDMO, who are going to catch up quite likely the externalized volume that they need to make, or the smaller players that are going to go straight to a CDMO for manufacturing. We're working with everybody. Now, the 20 companies that are evaluating us, that's not just in mRNA. Another big workflow that's coming through is sterility testing, so AVA. This is like our metagenomics assay or infectious disease. We're looking for bugs. The reason why our technology is used is if you want to do PCR and culture takes too long. PCR, you need to know what you're looking for, so it's like a panel. For us, everybody else is going fishing with a rod. We go fishing with a net. We capture everything that's in there.
Because of the value of our tech, we can also see if the DNA is replicating, and that tells you if it's alive. So now you can quantify and actually tell the customer, "You need to do something, what you need to do." Sterility testing is another one where we could shorten the time for batch release by about a week, and that could be used in things like mRNA drug production as well. It's a very big established market where we think we can offer quite a bit of value. Like I say, it's where the tech is already used in the human setting of infectious disease. It's very similar.
Yeah. Okay. Good. In terms of another key market segment is the clinical and sort of diagnostic side of things. Obviously, that is a significant opportunity. I think you have articulated that as a more of a mid to slightly longer term opportunity. I guess, how do you tackle that opportunity and what are the things you need to get in place and get everything working, so in terms of customer and technology development, so you can actually execute that market?
Yeah. Clinical is clearly, it is a bigger market opportunity for us arguably today, but it is much more diverse. If you think about biopharma, it is like 50 customers in reality, that you are going to go for in total. Multiple sites, but 50 customers. For clinical, it is thousands, because it is hospital networks, it is the big outsourced providers, it is multiple different types of customers. The size per customer is arguably a lot lower than those single big biopharma customers. In terms of where the tech is today, the reason why we have got this accelerating over time, but really we can see this accelerating further beyond the 2030 time horizon, whereas biopharma might get to a point and then maybe slow down a little bit. For clinical, it has got a longer tail duration of growth, and that is because we have got to still do some things with the product.
We got a roadmap. There is certain areas where we know we still need to kind of improve a little bit on accuracy. Not in all, but in certain applications. We know that we need to allow for higher throughput barcoding, which will allow for more samples per flow cell, and hence reduce the price, and that will allow greater uptake. We know that there is quite a bit we need to do on actually demonstrating the value and differentiation of the tech to the customer base more efficiently. What is the value of methylation? What is the value of long read? Long read is really well understood in rare disease. Structural variation, improving diagnostic yield, circa 30%, really well understood, driving the uptake. The value of methylation, understood, but not as well as it could be.
The fact is, we see more methylation than any other company, any other tech. As that kind of builds and we build that up, we think that will help with adoption as well. Lastly, bioinformatics backend. You talked about the partnering element. Front end, we need to partner with the automation players to allow for uptake by the big established customers. At the backend, we need bioinformatics to be solid, and tertiary analysis as well as secondary analysis. On those pieces, we are working on those, but some partnerships we need to form. Lastly, there is companies like our partners, bioMérieux, Danaher, and we will add more, that are going to help the uptake as well, because this is their expertise. This is their sweet shop, essentially, that we want to try and be part of as well.
Yeah. Okay. Makes sense. You've obviously, yeah, so mostly around direct market purchases of the technology, the products. You're also building on another aspect of the commercial piece, which is licensing agreements, particularly as it relates to the diagnostics deal that you announced in the summer.
It was a cross-licensing agreement around a specific product that could be quite significant financially, but presumably also strategically, in terms of other similar deals. Just a bit more around that, and is there something, it was a particular uniqueness around that particular cross-licensing that made that work, or are there further opportunities for similar licenses?
We do see opportunities for further licensing deals over time. This one, maybe not unique, but there aren't that many global diagnostics companies. There is a limited number of these in reality you're going to do. In this agreement, it's a cross-licensing agreement, like you say, where essentially we've been talking to that counterparty for best part of 18 months before we signed the deal. Negotiations really heated up in the last six months prior to signing, and we reached an agreement. We're very happy with it, where we get $20 million upfront. We've got the cash in the bank. They're committed to buying $15 million worth of product over the next two years. We can come back to that in a minute.
We also get a low to mid single-digit royalty on net sales of their product portfolio, where the cross-licensing of IP helped. We see 90% of the value being in that royalty. That's on an NPV basis where we're using a mid-teens discount rate. It's a quite high cash value. That's based on market expectations for that product set, and growth beyond, into the 2030s. We're very happy with this. We think this is, it's 100% gross margin on the royalty checks that are going to come through. Market expectations are for this product to be pretty large by 2030, and it's not in our guidance for over $700 million or greater than 15% EBITDA margin. It could quite materially change the shape of our P&L as well.
The thing that is kind of maybe beyond that is how the $15 million of product purchases could potentially lead into something, hopefully, more evolved with that customer in time as well. Going beyond even the, what we are looking at the moment.
Just on that, the risk profile of that scenario playing out from here in terms of the-
Nobody has got anything in the numbers, which is great. We have got very, let us just keep feet on the ground and low expectations. It is over two years, the product purchases, so it is going to take time to play through.
Sure. Okay, good. Should touch quickly on some competitive dynamics, so I guess more specifically around Roche and their launch of their AXELIOS technology, Nanopore pace, but more on the short-read side of things. Just observations, impact of anything that that has made in the market that is of note for you guys?
It's a good platform. It's a very high throughput system. We would say this, but you can go look at the materials. We wouldn't say it's really going up against us. We are not a super high throughput platform. We offer any read length, and I think for their platform, I think it's fair to say it's more in the short range. It's always difficult to talk about other people's tech, but more in the short range. We look at the DNA and RNA natively, directly, which means we get all of the methylation. They make a copy, so they're going to lose some of that, and there's going to be a need for a chemical workaround to get there. The form factor's very different, the size is very different, and the nanopore is very different.
Our nanopore we've refined over many years to be kind of like a perfect instrument of a microscope. Whereas the nanopores that are used maybe on other people's platforms, maybe earlier versions, I think it's fair to say. Don't get me wrong, when they use their Xpandomer technology and expand the DNA, they get a very clean electrical signal versus ours, which is very messy because it's looking at the DNA in its raw form. That's why they can kind of have the kind of scale they have as well. It's just a different approach. But it's much more, we believe, and we've said this for a while, and we think the investors see it as well, it's perhaps more targeting the high throughput counting applications, the short-read platforms that are out there. We think you're starting to see it, actually.
I think they said they placed out 35 devices in Q3. We'll see what happens in Q4. It's maybe not the worst thing in the world to have a bit more competition at that end of the market. Don't get me wrong, from a pricing, I'd rather there was no competitors and we were on our own, but that's not the case. But actually having a bit more competition there likely does lead to maybe a bit destabilizing of the status quo. In that, we can maybe show, we maybe have some opportunity as that fallout continues. We don't see them in head-to-head situations.
We've seen maybe one, and it was in a high throughput counting application that really maybe wasn't the right thing for us anyway, because it's just on a price per gig basis, we're never going to be in that ballpark until we release updated products that have higher throughput capability.
Okay, thank you. Then maybe just a few more minutes on overall for the group management and your guidance. New CEO has come in this year, Francis Van Parys. Just a few, just a reflection maybe of the areas that he is focusing on, getting the business focused on, and whether there is, what has been the summary shift change, if there has been any from him coming in?
Yeah, so joined in March, spent time listening internally, externally with customers, meeting with investors, and almost on the first day, well, actually even before then, we have been talking since December, is to kind of go through the foundational work I would say we did on the strategy, but then actually to kind of really double click, dig down, and understand, but also make sure complete alignment that we are going in the right direction with it all. So particularly on that where to play. Then really it is now that how to play from a product roadmap and an operational perspective, which we are going to detail to the market in results in February, so to give a bit more color. But it is really about being, building, and he spent a lot of time building the team.
As you know, we went through quite considerable management change last year, and we are now nearly at full complement. So we got CBDO hire coming in Q1, and one more person after that who is already signed, and then essentially we will be fully set. So building the team, ensuring the strategy is in the right direction, and then looking at the how the cadence of the business is what I would say, and that essentially how the business is operating and getting that in order to make more efficient. But more to come in February when we come to the product roadmap in particular.
Okay, thank you. Then just touch on guidance, particularly for this year at least, the 16%-20% underlying constant currency, 12% in the first half, confidence in that second half set up. Then as you think about the break-even target for 2027, what are the, you have done reasonable amounts of self-help, I think, on the cost base, so is it just more about the revenue generation top line, or have you got some gross margin to come?
Yeah, so 16%-20% this year ex the $20 million one-off, 23%-27% with the one-off, constant currency. Consensus currently has us, I think it is modeled around 16%, so the low end of that, and as a CFO, that is exactly where we want everybody to be. As consensus expectations are today for the top line revenue number, I believe it is GBP 270.7 million sterling, which let us keep everybody there. That does imply a big step up in the second half, but what I would just reiterate is we had that $10 million worth of projects that have rolled off, and we also had, we have got the UK Biobank contract that is ramping, and it should complete at the end of the year.
The other things that are kind of going on the numbers that with the noise around China and the export control restrictions, which essentially we have said it was 16% down as a country for us in the first half, not expecting that to improve in the second half, but excluding that APAC underlying growth and excluding the PRECISE contract was actually not bad. Just kind of that playing through normally. In Americas, we saw, it was a bit slower than we were anticipating, particularly the step up for these companies that are evaluating us, particularly in the clinical space, but they have now done that, and essentially we are seeing that ramp.
Yes, there is a step up in the second half, but to get to that 16%-20% range, same sort of visibility we had the year before actually, where we delivered to 24% for the full year. Yeah, again, in line with that. On EBITDA break-even, it is about delivering, at mid-teens level at the top line for next year as we have guided. Gross margin expansion, we have said 62% this year is an underlying number, we are 62.2% at the half year. We think that will go higher again next year, particularly because of recycling of the PromethION flow cell. On the cost base, it is about basically holding the cost flat. We have done a lot of self-help last year, two sets of restructurings that we went through. We reduced the product portfolio, took out some R&D projects as well.
We do not need to do something so drastic this time around, but those things were kind of aligned to the kind of strategy anyway. This is just about kind of operational discipline from here, but I think hopefully the market has seen that we are enforcing that now.
Okay. Thank you. I know we're slightly running over here, but there is one important topic we should just brief, a big topic, but not a long time to deal with, but AI. Obviously, there's been quite a bit of excitement generally in this space about AI potential, obviously massively deepening our understanding of biology, genomics. How do you Is there any particular examples where you kind of talked to already around sort of AI opportunities, or how do you see that as ultimately a market to play?
Yeah. What I'd say is that this has been a buyer for the data and the technology for some time. This is not a new thing, but it's absolutely getting a lot of focus now because of the amount of capital going into the foundation model companies, and we are seeing opportunities come through. Now, we're seeing some new buyers of the tech as well from the ground up, particularly the data infrastructure players, which is a bit interesting. This is something that needs probably 10 minutes on its own, in all honesty, but I would say that the tagline here really is, if you want the best AI, you need the best data. We provide the most complete data set from a genomics perspective. That's why we have a right to win in this space, and that's on the foundation model building.
We also think it's going to play through and like post this wave, when it comes about the agentic AI opportunity about like analysis and interpretation, where if you think about what tech is going to win at that point, it's going to be a tech that can be miniaturized, can be distributed, and offers in real time rich data, which is exactly what we can do. We're trying to play both waves and more to come.
Great. Thanks, Nick. Thanks for your time.
Thank you.
Apologies for overrunning slightly, but hope you have a productive conference. Thank you.